Improving quality of life through innovations in urology.
Get news and information for
healthcare professionals
Urovant Sciences
Vibegron
Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS).
Latest News
The latest posts and articles
-
Urovant Sciences to Report Second Fiscal...
on October 27, 2020
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Oct. 27, 2020-- Urovant Sciences […]
Read Latest Post -
Urovant Sciences Announces Co-Promotion...
on October 7, 2020
Agreement will supplement Urovant’s targeted sales and market access efforts in the launch of […]
Read Latest Post -
Urovant Sciences to Present at the H.C....
on September 8, 2020
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Sep. 8, 2020-- Urovant Sciences (Nasdaq: […]
Read Latest Post
View more
Copyright 2020 © All Rights Reserved